Prostanoids suppress the coronary vasoconstrictor influence of endothelin after myocardial infarction

Vincent J de Beer1, Yannick J Taverne, Diederik W Kuster

  • 1Division of Experimental Cardiology, Department of Cardiology, Thoraxcenter, Cardiovascular Research School COEUR, Erasmus Medical Center, Rotterdam, The Netherlands.

Insights

Myocardial infarction alters coronary blood flow regulation. After heart attack, nitric oxide

Area of Science:

  • Cardiovascular Physiology
  • Endothelial Function
  • Myocardial Infarction Research

Background:

  • Myocardial infarction (MI) causes endothelial dysfunction, disrupting the balance of endothelium-derived vasodilators and vasoconstrictors.
  • Previous research indicated that despite elevated endothelin (ET) plasma levels post-MI, its coronary vasoconstrictor effect is diminished.
  • Nitric oxide (NO) and prostanoids normally modulate ET's vasoconstrictor effect in healthy swine.

Purpose of the Study:

  • To investigate the interaction between NO, prostanoids, and ET in controlling coronary vasomotor tone in the non-infarcted myocardium after MI.
  • To assess the impact of endothelial dysfunction on these interactions during rest and exercise.

Main Methods:

  • Studies were conducted in chronically instrumented normal and MI swine.
  • Coronary vasomotor tone was assessed at rest and during treadmill exercise.
  • Inhibition of endothelial nitric oxide synthase (eNOS) using L-NNA and cyclooxygenase (COX) using indomethacin was performed.
  • Protein levels of eNOS and COX were measured in the non-infarcted myocardium.
  • The effects of L-NNA and indomethacin on coronary vasoconstriction and their interaction with the ET(A/B) receptor blocker tezosentan were evaluated.

Main Results:

  • eNOS inhibition (L-NNA) caused coronary vasoconstriction, with a slightly blunted effect in MI swine despite unchanged eNOS expression.
  • Cyclooxygenase inhibition (indomethacin) also caused coronary vasoconstriction, with similar effects in normal and MI swine, consistent with unaltered COX-1 expression.
  • L-NNA enhanced tezosentan's vasodilator effect during exercise in both groups, but this interaction was blunted in MI swine.
  • Indomethacin increased tezosentan's vasodilator effect during exercise in normal swine, but unmasked a vasodilator effect of tezosentan at rest and during exercise in MI swine.

Conclusions:

  • Endothelial control of coronary vasculature is altered in post-MI remodeled myocardium.
  • The overall vasodilator influence of NO and its inhibition of ET's vasoconstrictor effect were reduced post-MI.
  • Prostanoid vasodilator influence was maintained, but its inhibition of ET's vasoconstrictor effect was enhanced in remote myocardium post-MI.

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...